---
title: "The medical device industry receives significant benefits, and the list of high-growth overseas business revenue is released"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247046302.md"
description: "The National Medical Products Administration has drafted the \"Regulations on the Management of Export Sales Certificates for Medical Devices\" to support the export trade of medical device products. In the A-share medical device industry, 117 companies are expected to generate a total overseas revenue of 81.366 billion yuan in 2024, a year-on-year increase of 16.21%. Mindray has the highest overseas revenue, reaching 16.434 billion yuan, with a growth rate of 21.28%. Hanbon Technology, Endovastec, and Chunli Medical have overseas revenue growth rates of 103.52%, 99.35%, and 78.31%, respectively"
datetime: "2025-07-03T00:12:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247046302.md)
  - [en](https://longbridge.com/en/news/247046302.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247046302.md)
---

# The medical device industry receives significant benefits, and the list of high-growth overseas business revenue is released

The National Medical Products Administration has drafted the "Regulations on the Management of Export Sales Certificates for Medical Devices" to support the export trade of medical device products. According to statistics from the Securities Times, there are a total of 131 individual stocks in the medical device industry in the A-share market, of which 117 disclosed overseas business income amounts in their 2024 annual reports, totaling 81.366 billion yuan, an increase of 16.21% compared to 70.017 billion yuan in 2023. Mindray's overseas business income in 2024 is the highest, reaching 16.434 billion yuan, an increase of 21.28% compared to the same period last year; both Yingke Medical and Lanfan Medical have overseas business income exceeding 5 billion yuan in 2024. In terms of growth rate, among the medical device stocks with overseas business income exceeding 100 million yuan in 2024, Hanbon, Endovastec, and Chunli Medical have the highest year-on-year growth rates, reaching 103.52%, 99.35%, and 78.31%, respectively

### Related Stocks

- [688236.CN](https://longbridge.com/en/quote/688236.CN.md)
- [01858.HK](https://longbridge.com/en/quote/01858.HK.md)
- [300760.CN](https://longbridge.com/en/quote/300760.CN.md)
- [688016.CN](https://longbridge.com/en/quote/688016.CN.md)
- [688755.CN](https://longbridge.com/en/quote/688755.CN.md)
- [300677.CN](https://longbridge.com/en/quote/300677.CN.md)
- [002382.CN](https://longbridge.com/en/quote/002382.CN.md)

## Related News & Research

- [Trump faces record-low approval on inflation as retirees struggle](https://longbridge.com/en/news/286834439.md)
- [Should you lock in gains before summer or let your winners ride?](https://longbridge.com/en/news/286811229.md)
- [Comey eyes new 'anti-weaponization' fund: 'I'm guessing I'll be in line'](https://longbridge.com/en/news/286948735.md)
- [Scott Jennings voices concern over Trump's $1.7B DOJ fund](https://longbridge.com/en/news/286922300.md)
- [World is more vulnerable to pandemics despite Covid-19 lessons, warns WHO](https://longbridge.com/en/news/286895865.md)